DelveInsight Business Research, LLP: LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
EurekAlert!3d
Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
eLife5d
Identification and comparison of orthologous cell types from primate embryoid bodies shows limits of marker gene transferability
The authors have generated important resources such as a reference dataset of early primate development by utilizing single-cell transcriptomic technology together with induced pluripotent stem cells ...